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Polo-like kinase 1 (Plk1), a serine/threonine protein kinase
normally expressed in mitosis, is frequently up-regulated in
multiple types of human tumors regardless of the cell cycle
stage. However, the causal relationship between Plk1 up-regu-
lation and tumorigenesis is incompletely investigated. To this
end, using a conditional expression system, here we generated
Plk1 transgenic mouse lines to examine the role of Plk1 in
tumorigenesis. Plk1 overexpression in mouse embryonic fibro-
blasts prepared from the transgenicmice led to aberrantmitosis
followed by aneuploidy and apoptosis. Surprisingly, Plk1 over-
expression had no apparent phenotypes in the mice. Given that
no malignant tumor formation was observed even after a long
period of Plk1 overexpression, we reasoned that additional fac-
tors are required for tumorigenesis in Plk1-overexpressing
mice. Because Plk1 can directly participate in the regulation of
theDNAdamage response (DDR) pathway, we challenged Plk1-
overexpressingmice with ionizing radiation (IR) and found that
Plk1-overexpressing mice are much more sensitive to IR than
their wild-type littermates. Analysis of tumor development in
the Plk1-overexpressing mice indicated a marked decrease in
the time required for tumor emergence after IR. At the molecu-
lar level, Plk1 overexpression led to reduced phosphorylation of
the serine/threonine kinases ATM and Chk2 and of histone
H2AX after IR treatment both in vivo and in vitro. Furthermore,
RNA-Seq analysis suggested that Plk1 elevation decreases the
expression of several DDR genes. We conclude that Plk1 over-
expressionmay contribute to tumor formation by both inducing
chromosomal instability and suppressing the DDR pathway.
Chromosome instability and aneuploidy are hallmarks of
human cancers (1). Most human cancers contain aneuploid
cells, and a significant number of studies have pointed to failure
in various critical mitotic events as a cause of aneuploidy in
tumors (2–4). Defects in mitotic events, including centrosome
maturation, microtubule-kinetochore attachment, chromo-
some alignment, and completion of cytokinesis, are the causes
of aberrant cell division, eventually resulting in aneuploidy in
daughter cells (5, 6). The regulation of proper mitotic progres-
sion that is important to genomic integrity is predominantly
controlled by protein phosphorylation driven by several evolu-
tionarily conserved serine/threonine kinases, known as mitotic
kinases. The most prominent mitotic kinases include Polo-like
kinase 1 (Plk1), cyclin-dependent kinase 1 (Cdk1), aurora fam-
ily, and NIMA (never in mitosis A) family kinases (7).
The Polo gene was first cloned from Drosophila melano-
gaster, with the observation that mutations in Polo induced
abnormal spindle poles duringmitosis (8). Fivemammalian ho-
mologues for Polo, named Plk1 to Plk15, were soon identified
(9). Among them, the best characterized member of human
Plk family is Plk1. It has been well-documented that Plk1 is
involved in almost every step ofmitosis (10). Thus, it is probably
not surprising that Plk1 is overexpressed in many cancer types,
including melanoma, breast, non-small cell lung, colorectal,
prostate, pancreatic, ovarian, and head and neck cancers, as
well as non-Hodgkin’s lymphomas and acutemyeloid leukemia
(9, 11). More importantly, recent studies have also linked Plk1
with other cancer-associated pathways (12). For example,
cross-talk between Plk1 and the p53 tumor suppressor has been
described, because Plk1 negatively regulates both p53 protein
stability and nuclear localization (13, 14). In another study, Plk1
elevation was shown to cause PTEN inactivation, resulting in a
tumor-promoting metabolic state in prostate cancer cells (15).
In linewith this observation, Plk1-associated kinase activitywas
demonstrated to contribute to the low-dose arsenic-mediated
metabolic shift fromoxidative phosphorylation to glycolysis via
activation of the PI3K/AKT/mTOR pathway (16). In addition,
elevation of Plk1 leads to acquisition of resistance to various
therapies, including radiotherapy (17), taxol (18), metformin
(19), gemcitabine (20, 21), and androgen signaling inhibitors
(22). All these studies strongly suggest that Plk1 likely plays a
critical role during carcinogenesis.
Inhibition of cell proliferation and induction of apoptosis are
two basic principles of anticancer therapy. Antimitotic therapy
is a standard of care for many cancer types. Overexpression of
Plk1, observed in a broad spectrum of cancers, has often been
correlated with disease stage, histologic grade, poor prognosis,
metastatic potential, and survival (9). The key role of Plk1 in
oncogenic events gave impetus to the development of potent
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and specific small molecule Plk1 inhibitors (10). Consequently,
several Plk1 inhibitors have been developed, with some agents
showing encouraging results in various cancer cell lines and
xenograft models of human cancer (23, 24). Preclinical studies
have demonstrated a particular sensitivity to Plk1 inhibition in
human cancer cells harboring specific genetic abnormalities,
including mutations in p53, Ras, and PTEN (10). In contrast to
marked antitumor activity in leukemia, overall antitumor activ-
ity of Plk1 inhibitors in patientswith solid tumor has beenmod-
est in trials (23). Thus, there is a critical need for understanding
the physiological functions of Plk1 in vivo. Lack of Plk1 trans-
genic mice is one major hurdle to achieve that.
Herein, we generated a transgenic mouse model to investi-
gate the involvement of Plk1 in tumorigenesis. Using aCre-loxP
system, we achieved the conditional expression of Plk1. Ele-
vated Plk1 expression resulted inmitotic failure, leading to apo-
ptosis and aneuploidy inmouse embryonic fibroblasts (MEFs).2
In addition, Plk1 overexpression caused a defective DNA dam-
age response (DDR) pathway. Our findings indicated that this
mouse model is a useful system to study the physiological roles
of Plk1 in cancer etiology and therapeutics.
Results
Strategy and design for the conditional Plk1 transgenicmouse
Considering that overexpression of Plk1 induces abnormali-
ties in cell division in vitro, we selected a conditional transgenic
system to prevent the possible embryonic lethality of founder
animals (Fig. 1A). The configuration of this transgenic cassette
was chosen so that Plk1 would be overexpressed in the trans-
genicmice after expression of Cre recombinase. To prevent the
chromosomal positional effects associated with the random
nature of transgenic integration, we inserted the cassette into
thewell-characterized euchromatic locus Rosa26 (Fig. 1A). The
standard transfection procedures using this exchange vector
were followed by the recombinase-mediated integration, which
resulted in more than 90% positive embryonic stem (ES) cell
clones (Fig. 1, B–H). Plk1-KI mice were subsequently obtained
from the recombinant ES cells.
Establishment and characterization of transgenicmouse
founders for Plk1 expression
We successfully obtained four conditional transgenic found-
ers by pronuclear injection to mouse embryos. Female condi-
tional Plk1-KI mice were mated with male CMV-Cre trans-
genicmice that have a wide tissue distribution for expression of
Cre recombinase (25). Expression of Plk1 in CMV-Cre/Plk1-KI
double transgenic mice was detected in several organs with
quantitative RT-PCR (qRT-PCR) (Fig. 2A), immunoblotting
(IB) analysis (Fig. 2B), and immunohistochemistry (IHC) stain-
ing (Fig. 2C). Increase of Plk1 expression was also confirmed in
CMV-Cre/Plk1-KIMEFs (Fig. 2D). To further validate the Plk1
overexpression system, Plk1-KI mice were crossed withMyod-
Cre mice, which express Cre in a muscle-specific manner. As
indicated, Plk1 expression was detected only in muscle in
Myod-Cre/Plk1-KI mice (Fig. 2, E and F). These data indicate
that the Plk1 conditional transgenic system works properly in
vivo.
Elevated Plk1 expression leads tomitotic abnormalities and
apoptosis in late-passagemouse embryonic fibroblasts
Considering that Plk1 has multiple functions during the cell
cycle, we next examined the effects of Plk1 overexpression on
the proliferation and cell-cycle progression of MEFs. Overex-
pression of Plk1 was confirmed in MEFs isolated from two dif-
ferent CMV-Cre/Plk1-KI mouse lines (supplemental Fig. S1A).
Surprisingly, massive Plk1 overexpression had no apparent
impact on the proliferative activity of early-passage MEF lines
comparedwith controlMEFs (supplemental Fig. S1B). Further-
more, we assessed the potential correlation between Plk1 over-
expression and cell cycle distribution. Despitemuch higher lev-
els of the Plk1 expression in CMV-Cre/Plk1-KI lines, FACS
analyses showed no apparent increase in G2/M populations
compared with control MEF cells (supplemental Fig. S1iC).
Given that MEFs undergo abnormal mitosis and senescence at
late passages, we tested whether Plk1 overexpression affects
this process. Interestingly, induction of Plk1 overexpression
resulted in significantly increased abnormal mitotic figures in
late-passage MEFs (Fig. 3A). Staining by propidium iodide
showed various mitotic defects, including chromosome mis-
alignment, chromosome missegregation, and chromosome
bridges, observed at higher rates in late-passage Plk1-overex-
pressing MEFs (Fig. 3A). To further assess the chromosome
instability induced by Plk1 overexpression, we analyzed chro-
mosome spreads generated from serial passages of MEFs
according to the 3T3 protocol (Fig. 3B). The total number of
chromosomes in each cell was determined, and cells were
scored as diploid (2n  40) or aneuploid. Primary control
MEFs, under normal culture conditions, spontaneously be-
come aneuploidy. However, we found that Plk1-overexpressing
MEFs were significantlymore aneuploidy than controlMEFs at
later passages (Fig. 3B). Examination of the absolute number of
chromosomes per cell revealed a highly significant increase in
the frequency of di- and multinucleated cells compared with
control MEFs.
The proliferation of control and Plk1-overexpressing MEFs
at later passages was investigated using MTT assay. Control
MEF cells was observed to proliferate significantly faster than
the Plk1-KI cells at passage 5 (Fig. 3C). To determine whether
the growth arrest in the Plk1-KI MEFs was associated with cell
cycle defects, DNA content was analyzed. We found that
Plk1-KI cells at passage 5 caused a significant increase in the cell
number of cells in G2/M phase, concomitant with a significant
decrease in the percentage of cells in G0/G1 phase (Fig. 3D).
Furthermore, MEFs with overexpression of Plk1 exhibited a
substantial increase in the sub-G1 population, suggesting that a
large number of cells at G2/M phase underwent cell death (Fig.
3D). Using senescence-associated -galactosidase assay, we
found that Plk1-overexpressing MEFs displayed an increased
senescence phenotype (Fig. 3E).
2 The abbreviations used are: MEF, mouse embryonic fibroblast; DDR, DNA
damage response; IR, ionizing radiation; ES, embryonic stem; qRT-PCR,
quantitative RT-PCR; IB, immunoblotting; IHC, immunohistochemistry;
GTT, glucose tolerance test; FC, fold change; DEG, differentially expressed
gene; KI, knock-in; RMCE, recombination-mediated cassette exchange;
H&E, hematoxylin and eosin.
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Figure 1. Generation of Plk1-KI mice. A, recombination-mediated cassette exchange (RMCE) technology was used to generate Plk1-KI mice. The Rosa26
targeting vector, which comprises of the HygR and cytomegalovirus-enhancer/-actin (CAG)-LacZ, was inserted into the Rosa26 locus using recombination
cassette exchange in ES cells. The F3/FRT sites were oriented in opposite directions. The modified locus equipped with RMCE docking sites is called Rosa26
(RMCE). The exchange vector carries the following elements: a CAG promoter sequence, a loxP-flanked transcription termination cassette (STOP) containing a
combinationofpolyadenylation signals (humangrowthhormoneandsyntheticpolyadenylation signals), themousePlk1ORF togetherwithaKozak sequence,
the human growth hormone polyadenylation signal and an additional polyadenylation signal, the F3/FRT pair, and a truncated neoR (neomycin resistance)
gene for positive selection. A poly(A) signal is included to prevent the expression of truncated neoR and Plk1 gene at random integration sites. After the
exchange vector was transfected into the C57BI/6 ES cell line equipped with RMCE docking sites in the Rosa26 locus, the resulting clones, mediated by FLP
recombination, were isolated using positive NeoR selection (Rosa26; RMCE exchanged). ES cells were injected into diploid blastocysts, and chimera were
generated. Finally, cross-breeding of chimeric with C57BL/6mice to producemice heterozygous for the conditional targeted Plk1 transgene. The presence of
the transcription termination cassette prevents expression of Plk1 protein form the conditional KI allele. Plk1 will be expressed from the CAG promoter after
Cre-mediated deletion of the transcription termination cassette. The constitutive Plk1-KI allele can be obtained after Cre-mediated recombination. S, Sspl; B,
Bmtl; X, Xbal; P, Pacl. B–H, Southern blotting analyses of genomic DNA from ES cells. RMCE, Rosa26 (RMCE); #1–#6, six transgenic (tg) ES clones. B, genomic DNA
was digested with Sspl and analyzed using probe 1. The sizes of WT, Rosa26 (RMCE), and Rosa26 (RMCE exchanged) were 4.1, 9.8, and 7.5 kb, respectively. C,
genomic DNA was digested with Xbal and analyzed using probe 1. The sizes of WT, Rosa26 (RMCE), and Rosa26 (RMCE exchanged) were 4.7, 7.9, and 6.2 kb,
respectively.D, genomic DNAwas digestedwith Bmt1 and analyzed using probe 1. The sizes ofWT, Rosa26 (RMCE), and Rosa26 (RMCE exchanged) were 10.3,
11.8, and 15.3 kb, respectively. E, genomic DNA was digested with Pacl and analyzed using probe 2. The sizes of WT, Rosa26 (RMCE), and Rosa26 (RMCE
exchanged) were 7.9, 10.2, and 5.8 kb, respectively. F, genomic DNAwas digested with Bmtl and analyzed using probe 2. The sizes of WT, Rosa26 (RMCE), and
Rosa26 (RMCE exchanged) were 10.3, 7.4, and 3.2 kb, respectively. G, genomic DNA was digested with Sspl and analyzed using probe 3. The size of Rosa26
(RMCE exchanged) was 7.5 kb. In transgenic clones #1–#6, integration of neomycin-resistant gene was detectable, whereas, as expected, WT and Rosa26
(RMCE) showed no signal for the exchange vector.H, genomic DNAwas digestedwith Bmtl and analyzed using probe 3. The size of Rosa26 (RMCE exchanged)
was 15.3 kb. Integration of neomycin-resistant gene was observed in all six transgenic clones, but not in WT and Rosa26 (RMCE).
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Phenotypic analysis of Plk1-KI mice
The CMV-Cre/Plk1-KI double transgenic mice displayed no
apparent developmental abnormalities during mouse develop-
ment. They grew and gained weight normally during the first 9
months of their life. However, by 18 months of age CMV-Cre/
Plk1-KI mice exhibited slightly reduced weight compared with
WT littermates (Fig. 4A). Litter sizes were similar for CMV-
Cre/Plk1-KI andWTmice, ranging from 7 to 9 pups per litter.
The pups were born healthy and developed normally at a nor-
mal growth rate, maturing at the age of 3–4 weeks. Further, we
did not observe any obvious behavioral difference between
CMV-Cre/Plk1-KI and WT animals. However, a minor
reduced survival rate in Plk1-KI mice was observed, when the
mice were monitored up to 25 months of age (Fig. 4B). The
complete morphological analyses did not reveal significant his-
tological differences between the organs of CMV-Cre/Plk1-KI
mice andWT animals at the ages of both 1 and 11months (Fig.
4, C and D). To determine the consequences of Plk1 overex-
pression on whole-body energy balance, we performed indirect
calorimetry analyses. On a chow diet, CMV-Cre/Plk1-KI mice
showed a slightly higher energy expenditure than control mice,
as indicated by both slightly increased O2 consumption (Fig.
4E) and slightly increased CO2 production (Fig. 4F). Consider-
ing that Plk1 is critical for energy metabolism in cultured cells
(16), we examined the glucose uptake in a glucose tolerance test
(GTT). Glucose uptake from CMV-Cre/Plk1-KI mice was
slightly increased in comparison to WT littermates (Fig. 4G).
Given that Plk1 is essential for many mitotic events, we exam-
Figure 2. Plk1detection in the tissues of double transgenicmice (CMV-Cre/Plk1-KI).A, relative Plk1mRNA levels in the tissues of CMV-Cre/Plk1-KI animals
were compared with the levels in Plk1-KI but without Cre expression (Control, Ctrl) animals (mean S.D., n 3 for each tissue). B, total cellular protein was
prepared from the indicated tissues of adult CMV-Cre/Plk1-KI or controlmice and subjected to IB. C, animals were sacrificed at the age of 1month, followed by
anti-Plk1 IHC stainingof indicated tissues. Sections representing theorgansof control (Plk1-KI only) andCMV-Cre/Plk1-KImice.Bar, 200m.D, toppanel, whole
cell extracts from MEFs isolated from CMV-Cre/Plk1-KI and control animals were subjected to IB. Bottom panel, PCR of mouse genomic DNA (tail clips) are
presented. E, relative Plk1mRNA levels in the tissues ofMyod-Cre/Plk1-KI animalswere comparedwith the levels in control animals (mean S.D.,n3 for each
tissue). F, total cellular protein was prepared from the indicated tissues of Myod-Cre/Plk1-KI and control mice. **, p 0.05; ***, p 0.01.
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ined the proliferative activity in CMV-Cre/Plk1-KI mice by
staining Ki67 of various tissues. The proliferation index was
moderately increased only in the liver (see Fig. 6A).
Plk1-KI mice andMEFs are hypersensitive to DNA damage
Because no malignant tumor formation was detected in the
Plk1-overexpressing mice after a long latency, we then chal-
lenged Plk1-overexpressing mice with carcinogens to see
whether Plk1 overexpression affects carcinogenesis under
stimulation condition. Mounting evidence suggests that Plk1
directly participates in the regulation of DNA double-strand
break repair (26, 27).We therefore exploredwhether Plk1 over-
expression affects cellular response to DNA damage in vivo.
Cohorts of CMV-Cre/Plk1-KI and WT mice were irradiated
with 10 Gy of ionizing radiation (IR) and closely monitored for
radiation toxicity. Although60% of WT littermates (n 14)
survived beyond 50 days, over 80% of CMV-Cre/Plk1-KI ani-
mals (n  15) died within 50 days (Fig. 5A), indicating that
CMV-Cre/Plk1-KI mice were more sensitive to IR) than WT
littermates. To confirm this observation, we plated MEFs (WT
or CMV-Cre/Plk1-KI) at clonal density and exposed to increas-
ing doses of IR, followed by colony formation assay. In agree-
ment with the in vivo results, the viability of CMV-Cre/Plk1-KI
MEFs after IR was significantly impaired compared with WT
MEFs, indicating that Plk1-overexpressingMEFs aremore sen-
sitive to DNA damage induced by IR (Fig. 5B). In a separate
experiment, CMV-Cre/Plk1-KI and WT mice at the age of 10
weeks were exposed to a single dose of 5 Gy whole body -ray
irradiation and monitored for additional 4 months. CMV-Cre/
Plk1-KI, but not WT, mice showed severe dermatitis, scratch-
ing bloody areas in head, neck, and ears (Fig. 5C). Although
none of WT mice had tumors after 4 months, 10.3% of CMV-
Cre/Plk1-KI developed life-threatening spleen lymphomas, a
difference that was statistically significant (p 0.0386; Fig. 5D,
Figure 3. Plk1 overexpression causes aneuploidy and apoptosis in MEFs. A, Plk1 overexpression causes various chromosome segregation errors. Upper
panel, the left image shows a metaphase cell with misaligned chromosomes, whereas themiddle image is an example of anaphase cell with lagging chromo-
somes. The right image shows cells with a chromosome bridge. Arrows indicate various chromosome segregation defects described above. Bottom panel,
histograms showing the percentages of cells with various chromosome segregation errors in Plk1-overexpressing cells. B, representative chromosome spreading of
Plk1-overexpressingMEFs,withWTMEFsspreadingwith40chromosomes (left panel). Thepercentagesofaneuploidcellswerecalculated frommetaphasespreadsof
control (Ctrl) and Plk1-overexpressing MEFs at different passages cultured according to the 3T3 protocol (n 3 experiments with 50 spreads each) (right panel). C,
analysisofproliferationcapacityof control andPlk1-overexpressingMEFs.Cells atpassage5were seededatadensityof 1104 cells/well andmonitoredat indicated
times by cell counting. D, flow cytometric analysis of cell-cycle distribution of late-passage of Plk1-overexpressing MEFs. The cells were collected, stained with
propidium iodide, and subjected to DNA content analysis with flow cytometry. Histograms on the right show the average percentages of cells in G0/1, S, and G2/M
phases. E, senescence assay for control and Plk1-overexpressingMEFs. The cells were fixed and subjected to senescence associated-galactosidase assay.
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bottom panel). Upon IR, CMV-Cre/Plk1-KI mice showed
apparent splenic enlargement and disruption of normal splenic
architecture, forming diffused lymphoma (Fig. 5D, top panel).
Increased radiation sensitivity is one of the hallmarks of defec-
tive DDR. The results described above suggested that Plk1 ele-
vation leads to inhibition of DDR. To directly test this hypoth-
esis, we analyzed DDR of mice. Spleens were prepared from
three differentmice that were exposed to IR and subjected to IB
to follow the DDR pathway. IR led to activation of DDR, indi-
cated by elevated phosphorylation ofATM,Chk2, andH2AX in
WT, but not in CMV-Cre/Plk1-KI mice (Fig. 5E). Finally, IR
also led to activation of the ATM/Chk2 pathway inWT but not
in CMV-Cre/Plk1-KI MEFs (Fig. 5F).
Overexpression of Plk1 leads to increased proliferation and
hypersensitivity to DNA damage in liver
Because liver is the only tissue that showed increased prolif-
eration upon Plk1 overexpression in the absence of IR (Fig. 6A),
we further analyzed liver-associated phenotypes after IR. A
4-fold increase in liver tumors inCMV-Cre/Plk1-KI versusnor-
mal littermates was observed (p  0.0472; Fig. 5D, bottom
panel). Upon IR, the livers of CMV-Cre/Plk1-KI mice were
apparently enlarged and carrying small tumors compared with
WT controls (Fig. 6B). IR of WTmice led to multifocal lymph-
oid hyperplasia, seen in a perivascular location (Fig. 6C, top
panel). For IR-treated CMV-Cre/Plk1-KI mice, we observed
multiple lymphocytic overgrowth in the parenchyma and
mitotic figures, suggesting the formation of mild lymphoma
(Fig. 6C, middle panel) or severe lymphoma (Fig. 6C, bottom
panel). To determine whether lymphoma in IR-treated CMV-
Cre/Plk1-KImice is of T-cell or B-cell origin, we stained a T cell
marker with CD3. Approximately 80–90% of the neoplastic
round cells demonstrated moderate to strong positive staining
with CD3 antibody, indicative of T lymphocyte origin (Fig. 6D).
Further, Ki67 IHC stainingwas performed to the same samples.
Ki67 signal was virtually undetectable in WT samples but sig-
nificantly increased in lymphoma areas of CMV-Cre/Plk1-KI
mice (Fig. 6E). Finally, we also observed apparent diffuse and
sever fatty change in the parenchyma of liver of one CMV-Cre/
Plk1-KI mouse (Fig. 6F).
To understand how Plk1 overexpression accelerates IR-in-
duced cancer formation, we performed an RNA-Seq analysis of
MEFs under different conditions ( Plk1-KI IR irradiation).
Expression levels of 648 genes were affected upon Plk1 overex-
Figure 4. Phenotypic analyses of Plk1-KI mice. A, the body weights of control (Ctrl) and CMV-Cre/Plk1-KI mice at different ages. Open and shaded bars
correspond to control and CMV-Cre/Plk1-KI mice, respectively. The values are means the standard errors of means. A Student’s t test was used to calculate
p values (n  7–11 mice per group). B, survival of control versus Plk1-KI mice (n  15–17 mice/group) over a period of 25 months. C and D, animals were
sacrificed at the ages of 1 or 11 months, followed by H&E staining of indicated tissues. Sections representing the organs of control and CMV-Cre/Plk1-KI mice
are shown. Bars, 200 m. E and F, Plk1 overexpression increases energy expenditure in mice. Male mice fed with regular chow were subjected to indirect
calorimetry. Oxygen consumption (E) and carbon dioxide release (F) were determined in control and CMV-Cre/Plk1-KI mice in metabolic chambers (n 
6/group).G, Plk1 overexpression results in increasedglucose uptake in aGTT. 2-month-oldmalemicewere starved for 16 h and injectedwith glucose, followed
by measurement of blood glucose levels at the indicated times.
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pression, whereas most of the affected genes were down-regu-
lated. In the presence of IR irradiation, Plk1 overexpression led
tomodulation of 227 genes (Fig. 7,A andB). This observation is
expected because it has been documented that Plk1 is a target of
DNAdamage. Plk1 KI affects the expression of 97 genes in both
the presence and the absence of IR irradiation. Detailed
description and analysis of RNA-Seq data will be reported sep-
arately. Herein, we only focus on genes related to DNA damage
repair pathways. As indicated in Fig. 7C, Plk1 overexpression
clearly affects the expression of a series of DNA damage repair
genes. In addition, RT-PCR was performed to confirm this
observation (Fig. 7D). Thus, deregulation of DNA damage
repair pathways uponPlk1 overexpression is the likely reason to
explain the enhanced IR-induced cancer formation.
Discussion
Mitotic kinases are critical regulators of cell cycle progres-
sion, and the timing of expression and activities of those kinases
are tightly regulated during the cell cycle. Plk1 is associated
withmitotic spindle poles and centromere/kinetochore regions
and the expression and activity of Plk1 peak during late G2 toM
phase (9, 10). Although the majority of studies highlights the
Figure 5. Plk1-KImice are hypersensitive to IR.A, survival plot to compare survival of CMV-Cre/Plk1-KI and control (Ctrl)mice afterwhole body IRwith 10Gy.
B, MEFs from control and CMV-Cre/Plk1-KI mice were plated at clonal density and subjected to increasing doses of IR. The number of colonies appearing after
10 days on the irradiated plates indicate the reduced viability of Plk1-overexpressingMEFs upon IR exposure. To quantify the number of cells remaining on the
plates after IR, sampleswere stainedwithMTT and lysed, and absorbancewasmeasuredwith a standard plate reader. The values reported aremeans S.D. of
three independent experiments (bottom panel). **, p 0.01. C, mice at the age of 10 weeks were subjected to 5 Gy whole body irradiation and imaged after 4
months. D, top panel, representative H&E-stained sections of spleen of CMV-Cre/Plk1-KI and control mice after 5 Gy whole body IR as in C. Bottom panel,
CMV-Cre/Plk1-KI animals develop elevated levels of spleen and liver tumors after exposure to IR. E, mice (CMV-Cre/Plk1-KI or control) were either left untreated
or exposed to 12.5 Gy of IR and sacrificed at 4 h post-irradiation. Spleen sampleswere analyzed by IBwith the indicated antibodies. F, MEFs of CMV-Cre/Plk1-KI
or control animals were irradiated at the indicated doses, followed by IB with indicated antibodies.
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essential role of Plk1 formitosis, overexpression of Plk1 is often
observed in interphase of many cancer cell lines and tumor
samples. In addition to these pathological observations, evi-
dence that Plk1 overexpression in NIH3T3 cells induces tumor
formation in nude mice suggests that dysregulation of Plk1
expression is a potential cause of sporadic malignant tumors
(28). These observations have prompted research into the
potential therapeutic application of Plk1 inhibition in cancer.
Mitotic catastrophe and tumor growth inhibition have been
observed in preclinical studies using Plk1 inhibitors or siRNAs
(12, 29). However, with all the evidence pointing to Plk1 as a
worthwhile cancer target, it should be noted that themolecular
evidence of Plk1 being a bona fide oncogene is still lacking.
Accordingly, we have established a Plk1 transgenic mouse line
to achieve overexpression of Plk1 with a new conditional trans-
genic system. In this system, the expression of Plk1 is regulated
by the recombination with the transgene mediated with Cre
protein and its target sequences.
Previous cellular studies indicate that sustained overexpres-
sion of Plk1 increases the oncogenic potential of cultured cells
(28). Herein, we have taken advantage of a conditional expres-
sion model to modulate the expression of Plk1. Our data based
on MEFs confirmed the effect of Plk1 overexpression on the
generation of misaligned chromosome and aneuploidy. We
have also observed that Plk1 overexpression induces apoptosis
in cultured MEFs at later passages. Several studies have indi-
cated that expression of activated oncogenes, such as Aurora-A
or Myc, generally induces apoptotic cell death in MEFs. Fur-
ther, apoptotic cell death induced byAurora-A orMyc has been
demonstrated to be p53-dependent (30–32). Because studies
Figure 6. Increased incidence of lymphoma or severe fatty change in the Plk1-KI mice after radiation. A, overexpression of Plk1 in the liver of the
CMV-Cre/Plk1-KI mice. B–F, mice (control (Ctrl) or CMV-Cre/Plk1-KI) were euthanized 40 days after 5 Gy whole body IR. B, representative images of liver at the
end of studywith green arrows indicating the tumors on the surface. C, representative images of H&E staining of liver sections frommicewith black and yellow
arrows indicating the mild and severe lymphomas, respectively. D, IHC staining for T cell marker CD3 with the sections in C with red arrows indicating the
positive CD3 signals. E, IF staining for the Ki67with sections inC. F, representative images ofH&E stainingof liver section fromoneof the Plk1-KImicewithwhite
arrows indicating severe fatty change.
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have also revealed a connection between Plk1 and p53, it is
possible that p53 might be involved in apoptosis of MEFs with
deregulated Plk1. It was shown that Aurora-A overexpression
inmammary epithelial cells results in increased apoptosis, with
a low frequency of tumor formation that is accelerated in a
p53-null background (32). It should be interesting to test
whether Plk1 overexpression accelerates tumor formation in a
p53-null background.
To our surprise, Plk1 overexpression alone is not enough to
drive cancer initiation, indicating that additional genetic mod-
ifications are required for tumor formation. Of note, inducible
Plk1 knockdown mice described previously did not show any
significant phenotype either (33). Increasing evidence suggests
that Plk1 is directly involved in overall DNA damage response,
including DNA damage checkpoint activation, checkpoint
maintenance, damage recovery, and DNA repair (34). Accord-
ingly, we challenged Plk1-overexpressing mice with IR to ask
whether Plk1 overexpression affects DDR pathway. Indeed,
Plk1 overexpression clearly showed increased radiation sensi-
tivity and accelerated IR-induced carcinogenesis inmice. Based
on our observation, we postulate that Plk1 is a critical regulator
of IR-induced carcinogenesis, likely because of premature
Figure7.Plk1overexpression inhibits expressionofDNAdamage repairgenes.A, heatmapof averagegeneexpressionandFCof total 875DEGsbetween
Plk1 KI and control forWT and irradiation, respectively. TheDEGswere sorted by the FCs from the highest to the lowest and separated into three groups: group
I, 648 DEGs for WT only; group II, 97 DEGs for both WT and irradiation; and group III, 130 DEGs for irradiation only. B, Venn diagram of numbers of DEGs for WT
and for irradiation. It shows statistically significant overlap between two groups of DEGs (p  1.7e-58). C, FCs of DEGs associated with DNA damage/repair
based on gene ontology association. D, RT-PCR of DNA damage/repair genes of MEFs (WT versus Plk1-KI).
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checkpoint termination and reduced DNA repair in Plk1-KI
mice.
We understand that most of previous studies suggested that
Plk1 plays an important role in turning off the later stages of
DDR. Interestingly, we recently found that Plk1 also phosphor-
ylates key factors upstream of ATM/ATR and regulates their
DDR-related functions in human cells. Specifically, Plk1
directly phosphorylates Mre11, a component of the Mre11–
Rad50–Nbs1 complex, at serine 649 during DDR. Phosphoryl-
ation of Mre11 inhibited loading of the Mre11–Rad50–Nbs1
complex to damaged DNA, leading to checkpoint termination
and inhibition ofDNA repair (35). This is one likelymechanism
to explain why Plk1 KImice are hypersensitive to ionizing radi-
ation, because Plk1-overexpressed cells will continue to cycle
even in the presence of DNA damage, eventually resulting in a
much higher chance for tumorigenesis. In addition, Plk1-KI
leads to inactivation of p53 and PTEN, two most important
tumor suppressors. This statement has been supported by
many of our previous publications. For example, we once
showed that Plk1 depletion leads to p53 stabilization (36).
Mechanistically, we later showed that Plk1 phosphorylation of
GTSE1 and Topors, two negative regulators of p53, results in
p53 inactivation (13, 14). Directly related to Plk1-KI mouse
work, we recently showed that Plk1 KI causes p53 inactivation
in MEFs (37). Finally, our RNA-Seq analysis provided in Fig. 7
of this manuscript clearly showed that additional DNA damage
repair genes are down-regulated upon Plk1 overexpression.
Thus, Plk1-KI-associated increased cancer formation upon IR
is likely due to multiple factors.
Materials andmethods
Animal experiments
All procedures involving mice were guided by Purdue
University Animal Care and Use Committee (Protocol no.
1111000133E001). Mice housed in the animal facility with free
access to standard rodent chow and water were under patho-
gen-free conditions and maintained in a 12-h light/12-h dark
cycle.
Isolation of total RNA frommurine tissues
After Plk1-KI and WT mice were quickly killed, different
organs were prepared and stored in RNAlater stabilization re-
agent (Qiagen). For the RNApreparation, tissue pieces of 20mg
were dispersedwith a PCR tissue homogenizing kit, followed by
total RNA isolation using an RNeasy mini kit (Qiagen).
Establishment of MEFs derived fromWT and Plk1-KI embryos
After removing the head and organs of embryos at day 13.5,
the tissue was minced and rinsed with PBS, followed by incu-
bation with 0.5 ml of 0.1% trypsin for 20 min at 37 °C. Trypsin
was inactivated by addition of 5 ml of DMEM supplemented
with 10% FBS. After centrifugation, the cell pellets were resus-
pended with DMEM and plated onto a 10-cm dish. Medium
was changed to remove the large clumps after 24 h. For Plk1-KI
MEFs, 5  106 cells were treated with 1 mM 4-hydroxytamox-
ifen for 48 h to induce Plk1 expression. The genotypes of
embryos were detected by PCRwith primers that are specific to
the Plk1 sequence. The cellswere cultured at 37 °Cwith 8%CO2
in DMEM supplemented with 10% (v/v) fetal calf serum, peni-
cillin, streptomycin, and 50 M 2-mercaptoethanol. The MEFs
were frozen as stocks at the second passage and used for subse-
quent studies.
Plk1 expression analysis
Real-time RT-PCR was carried out using the primer pairs
5-TAATGACTCAACACGCCTGATT-3 and 5-AGCTCA-
GCAGCTTGTCTACCAT-3. The -actin-specific primers
were used as controls: 5-GAGGAGCACCCCGTGCTGC-3
and 5-CCTGCTTGCTGCTGATCCACA-3. To quantify
Plk1 transcripts, 1 g of RNA was subjected to qRT-PCR. The
qRT-PCR was conducted using a TaqMan gene expression
assay for murine Plk1. As an internal control in the TaqMan
assay, murine -actin was used (Applied Biosystems). In brief,
the 10-l PCR included 1 l of RT product, 1 TaqMan Uni-
versal PCRMasterMix, 0.2l of TaqManprobe, 1l of forward
primer, and 1 l of reverse primer. The reactions were incu-
bated in a 96-well plate at 95 °C (10 min), followed by 40 cycles
of 95 °C (15 s) and 60 °C (1 min). All reactions were run in
triplicate.
Analysis of mouse genotypes
To test the genotype of WT or Plk1-KI mice, genomic DNA
was prepared from tail clips 0.5–0.8 mm in length with Viagen
Direct PCR-Tail reagent (Peqlab Biotechnologie, Erlangen,
Germany) according to the manufacturer’s protocol. For the
standard PCR, 10 ng of genomic DNA was amplified using the
sense primer 5-ACTTCGTATAGCATACATTATACGAAG-
TTATC-3 and the antisense primer 5-TCCTTTACCC-
AGAAAGCGC-3.
Antibodies
Although the antibodies against ATM (100–104) and phos-
pho-ATM (Ser(P)-1981) (100–81803) were purchased from
Novus Biologicals, the antibodies against phospho-Chk2
(Thr(P)-68) (2661), Chk2 (2662) were obtained from Cell Sig-
naling. The antibodies against -H2AX (22551) were from
Abcam,whereas the antibodies against Plk1 (05-844)were from
Millipore.
Immunoblotting
Cell lysates were prepared in TBSN buffer (20 mM Tris-HCl,
pH 8.0, 1mMEDTA, 0.5mMNa3VO4, 5mMEGTA, 1%Nonidet
P-40) supplemented with 150mMNaCl. For immunoprecipita-
tion, lysates were incubated with antibodies in TBSN at 4 °C
overnight, followed by three washes with TBSN plus 500 mM
NaCl and three more washes with TBSN plus 150 mM NaCl.
FACS analysis
The cells in culture dishes were trypsinized, washed with
PBS, and fixed in 95% ice-cold ethanol overnight. After centrif-
ugation, the cells were resuspended in PBS and incubated with
50 mg/ml propidium iodide in the presence of 100 units/ml
RNase A, followed by FACS analysis.
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Measurement of energy expenditure
Oxygen consumption (VO2) and carbon dioxide production
(VCO2) weremeasured under a consistent environmental tem-
perature and light cycle using an indirect calorimetry system
(Oxymax; Columbus Instruments). After the male mice were
acclimated to themetabolic chamber for 2 days, VO2 andVCO2
were measured in each individual mouse at 15-min intervals
during a 48-h period.
Glucose tolerance test
GTTwas performedby intraperitoneal injection of D-glucose
(Sigma) at a dose of 2mg/g bodyweightwith anOnetouchUltra
glucometer (Lifescan) into male mice after an overnight fast.
Blood glucose levels were then measured at different times (15,
30, 45, 60, 75, and 90 min).
Chromosome aneuploidy
After cells were treated with 50 ng/ml colchicine for 4 h, the
cells were collected and hypotonically swollen in 75 nM KCl for
30 min at 37 °C. The cells were fixed in freshly made Carnoys
fixative solution (75% methanol, 25% acetic acid) with three
changes of fixative. The cells were then dropped onto glass
slides and dried at room temperature. Chromosomes were
stained with DAPI for 30 m, rinsed with PBS three times, and
mounted.
Tumor analysis and histopathology
Aged mice were sacrificed by cervical dislocation following
anesthetization with isofluorine. Necropsies were performed,
and tissues as well as tumors observed by gross inspection were
fixed in 10% formalin 2 days and then embedded in paraffin. For
IHC analysis, representative sections were deparaffinized,
rehydrated in graded alcohols, and processed using the avidin-
biotin immunoperoxidase method. Sections were subjected to
antigen retrieval by microwave oven treatment using standard
procedures.
RNA-Seq analysis
MEFs were irradiated with 2 Gy -ray, incubated for 12 h,
and harvested for RNA extraction. Total RNA was extracted
from 1  107 cells using TRIzol reagent (Life Technologies),
followed by purification with the RNeasy mini kit (Qiagen)
based on themanufacturer’s instructions. Quality of input total
RNA was assessed using an Agilent Bioanalyzer RNA nano
chip. Libraries were constructed largely as directed by the Illu-
mina TruSeq Stranded mRNA sample preparation guide (cata-
log no. RS-122-9004DOC), using reagents from the Illumina
TruSeq RNA library preparation kit (catalog nos. RS-122-2001
and RS-122-2002). Briefly, poly(A) RNA was isolated by
annealing biotinylated oligo(dT) to total RNA, followed by cap-
ture with streptavidin-conjugated magnetic beads. Non-bound
RNAswere then largely removed by discarding the supernatant
after magnetic pelleting of Ampure beads. More binding buffer
was added followed by an 80 °C incubation to strand denature
all RNA from the oligo(dT) captured poly(A) RNA, followed
by another cycle of binding and supernatant removal. The
poly(A) RNA was eluted in a divalent cation and hexamer
first-strand synthesis primer containing buffer and fragmented
with a 4-min incubation at 95 °C. Reverse transcriptase in the
presence of actinomycinD to repress anyDNA-templatedpoly-
merization was used to synthesize first-strand synthesis of
cDNA. Second-strand synthesis was performed, replacing
dTTP with dUTP, which largely eliminates second-strand
amplicons during subsequent amplification. cDNA ends were
repaired, 3-adenylated, and ligated to Illumina adapters. Prod-
ucts were subjected to a 0.8:1 Ampure:sample purification to
reduce lower molecular weight amplicons, and the resulting
libraries were assessed with an Agilent DNA high sensitivity
chip for yield. Based on the overall yields, it was surmised that 8
cycles of amplification, rather than the 15 cycles recommended
by the Illumina protocol, would be used. Amplified final librar-
ies were titered for clustering using a KAPA library quantifica-
tion kit Illumina (KAPA catalog no. KR045), pooled, and clus-
tered in a single HiSeq 2500 v2 Rapid Chemistry lane to
generate 60 base single reads. To analyze the data, all sequenced
libraries were mapped to the mouse genome (UCSC mm10)
using STAR RNA-Seq aligner (37). The uniquely mapped reads
were assigned to mm10 refGene genes using featureCounts
(from subread) (38). The data were normalized using TMM
(trimmedmean of M values) method. The gene expression was
finally summarized on base-2 logarithmic scale. We excluded
genes with average expression level lower than 1 for all pheno-
types. Differential expression analysis was performed using
edgeR with paired samples setting (39, 40). The false discovery
rate was computed from p values using the Benjamini-Hoch-
berg procedure. Genes with false discovery rates of 0.05 and
absolute values of fold change (FC) larger than 1.5 were consid-
ered as differentially expressed genes (DEGs).
Statistical analysis
All data are presented as means  S.D. Statistical calcula-
tions were performed with Microsoft Excel analysis tools.
Although a two-tailed, unpaired Student’s t test was used to
assess the difference between the effects of treatment in cell
lines, one-way analysis of variance was used to determine sta-
tistically significant differences from the means in the animal
study. p values of 0.05 were considered statistically signifi-
cant. *, p 0.05; **, p 0.01.
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